By contrast, littleamplification of SIRT1 or SIRT6 was observed in similar analyses (data not shown).Moreover, we show that in a set of prostate carcinoma samples, the SIRT7amplifications are selectively detected in metastatic tumors with poor clinicaloutcome, and not observed in primary tumors with better patient survival.Finally, we demonstrate a strong inverse correlation between levels ofSIRT7 and E-cadherin, a marker of aggressive tumor stages and poorclinical prognosis17, 18. The gene discussed is CDH1; the disease is prostate carcinoma.